Research

Acute Lymphoblastic Leukemia - Understanding Mercaptopurine Levels

Ethnic and Racial Differences in Survival in Children with Acute Lymphoblastic Leukemia

Protocol Description

The purpose of this Children's Oncology Group study is to find out if there are differences in the way patients in the latter stages of treatment for acute lymphoblastic leukemia (ALL) handle the immunosuppressive drug mercaptopurine. Researchers will compare mercaptopurine levels to better understand how the body takes up or breaks down the drug as well as how well participants adhere to their treatment plan, with assessments done according to ethnic and racial lines. Researchers hope to gain information so that doctors can develop better treatments to improve survival rates for childhood ALL in all ethnic groups. Approximately 40 participants will be enrolled through Children’s Hospital of Pittsburgh of UPMC.

Eligibility Criteria

Patients up through age 21 that are receiving mercaptopurine as part of maintenance/continuation chemotherapy for ALL will be asked to participate.
Boys: Up through age 21
Girls: Up through age 21

Requirements
Participants will be asked to take all prescribed doses of mercaptopurine during the study using a MEMS® medication bottle with a special cap that electronically records when the medication bottle is opened. Additionally, blood samples will be taken at specific intervals during the study period.
Visits: 7
Duration: 6 months

Status: Open for Enrollment

Source of Support
Children’s Oncology Group (Study AALL03N1)
National Cancer Institute

Additional Resources
Children’s Oncology Group CureSearch
Study Description at National Institutes of Health